Acute urticaria and angioedema: Diagnostic and treatment considerations

American Journal of Clinical Dermatology

Volumn 10, Issue 4, 2009, Pages 239-250

  Frigas, Evangelo ^a   Park, Miguel A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ALLERGEN; AMOXICILLIN; AMPICILLIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHISTAMINIC AGENT; BETA LACTAM ANTIBIOTIC; CETIRIZINE; CINRYZE; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID; DESLORATADINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; DOXEPIN; ECALLANTIDE; ESTROGEN; FEXOFENADINE; FIBRINOLYTIC AGENT; FOOD ADDITIVE; HYDROCORTISONE; HYDROXYZINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; LORATADINE; METHYLPREDNISOLONE; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; RHUCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANAMNESIS; ANAPHYLACTIC SHOCK; ANGIONEUROTIC EDEMA; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTACT ALLERGY; DIAGNOSTIC PROCEDURE; DIET SUPPLEMENTATION; EMERGENCY WARD; EVIDENCE BASED MEDICINE; HUMAN; INFECTION; INSECT STING; MEASLES LIKE RASH; MORNING DOSAGE; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; SCORING SYSTEM; SKIN DEFECT; SKIN TEST; URTICARIA; VACCINATION;

ACUTE DISEASE; ADRENERGIC AGENTS; ANGIOEDEMA; CAUSALITY; COMPLEMENT C1 INHIBITOR PROTEIN; DRUG THERAPY, COMBINATION; EMERGENCY MEDICAL SERVICES; EPINEPHRINE; GENETIC PREDISPOSITION TO DISEASE; GLUCOCORTICOIDS; HISTAMINE ANTAGONISTS; HUMANS; LEUKOTRIENE ANTAGONISTS; PROGNOSIS; URTICARIA;

EID: 67650641505     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/00128071-200910040-00004     Document Type: Review

References (113)

1. Kaplan A. Urticaria and angioedema. In: Adkinson NFYJ, Busse WW, Bochner BS, et al., editors. Middleton's allergy principles and practice. 6th ed. Philadelphia (PA): Mosby, 2003: 1537-58
2. Mathews KP. Urticaria and angioedema. JAllergy Clin Immunol 1983;72 (1): 1-14
3. Champion RH, Roberts SO, Carpenter RG, et al. Urticaria and angio-oedema: a review of 554 patients. Br J Dermatol 1969; 81 (8): 588-97
4. Gaig P, Olona M, Munoz Lejarazu D, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004; 14 (3): 214-20
5. Bigby M, Jick S, Jick H, et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 con secutive inpatients, 1975 to 1982. JAMA 1986; 256 (24): 3358-63
6. Grattan CE, Humphreys F, British Association of Dermatologists Therapy guidelines and Audit Subcommittee. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol 2007; 157 (6): 1116-23
7. Zuberbier T, Bindslev-Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 2006; 61 (3): 316-20
8. Mortureux P, Leaute-Labreze C, Legrain-Lifermann V, et al. Acute urticaria in infancy and early childhood: a prospective study. Arch Dermatol 1998; 134 (3): 319-23
9. Volcheck G. Clinical allergy diagnosis and management. 1st ed. New York: Springer, 2009: 279-309
10. Council for International Organizationof Medical Sciences. Harmonizing use of adverse drug reaction terms: definitions of terms and minimum require ments for their use: respiratory disorders and skin disorders. Pharmaco-epidemiol Drug Saf 1997; 6: 115-27
11. Litt J. Drug eruption reference manual. 14th ed. New York: Informa Healthcare, 2008: 1-657
12. Zuberbier T, Greaves MW, Juhlin L, et al. Definition, classification, and routine diagnosis of urticaria: a consensus report. J Investig Dermatol Symp Proc 2001; 6 (2): 123-7
13. Shin HT, Chang MW. Drug eruptionsinchildren. Curr Probl Pediatr 2001; 31 (7): 207-34
14. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977; 21 (3): 247-54
15. Kramer MS, Leventhal JM, Hutchinson TA, et al. An algorithm for the operational assessment of adverse drug reactions: I. Background, description, and instructions for use. JAMA 1979; 242 (7): 623-32
16. Hutchinson TA, Leventhal JM, Kramer MS, et al. An algorithm for the operational assessment of adverse drug reactions: II. Demonstration of reproducibility and validity. JAMA 1979; 242 (7): 633-8
17. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (2): 239-45
18. Assem E. Drug allergy and tests for its detection. 5th ed. London: Chapman and Hall Medical, 1998: 791-815
19. Anonymous. Executive summary of disease management of drug hyper-sensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1999; 83 (6 Pt 3): 665-700
20. Frigas E, Park MA, Narr BJ, et al. Preoperative evaluation of patients with history of allergy to penicillin: comparison of 2 models of practice. Mayo Clinic Proc 2008; 83 (6): 651-62
21. Kalogeromitros D, Rigopoulos D, Gregoriou S, et al. Penicillin hypersen-sitivity: value of clinical history and skin testing in daily practice. Allergy Asthma Proc 2004; 25 (3): 157-60
22. Macy E, Mangat R, Burchette RJ. Penicillin skin testing in advance of need: multiyear follow-up in 568 test result-negative subjects exposed to oral penicillins. J Allergy Clin Immunol 2003; 111 (5): 1111-5
23. Pichichero ME, Pichichero DM. Diagnosis of penicillin, amoxicillin, and cephalosporin allergy: reliability of examination assessed by skin testing and oral challenge. J Pediatr 1998; 132 (1): 137-43
24. Sogn DD, Evans III R, Shepherd GM, et al. Results of the National Institute of Allergy and Infectious Diseases Collaborative Clinical Trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med 1992; 152 (5): 1025-32
25. Solley GO, Gleich GJ, Van Dellen RG. Penicillin allergy: clinical experience with a battery of skin-test reagents. J Allergy Clin Immunol 1982; 69 (2): 238-44
26. Aoki T, Kojima M, Horiko T. Acute urticaria: history and natural course of 50 cases. J Dermatol 1994; 21 (2): 73-7
27. Legrain V, Taieb A, SageT, et al. Urticaria in infants:a study of forty patients. Pediatr Dermatol 1990; 7 (2): 101-7
28. Sampson HA. Adverse reactions to foods. In: Adkinson DFYJ, Busse WW, Bochner BS, et al., editors. Middleton's allergy principles and practice. 6th ed. Philadelphia (PA): Mosby, 2003: 1619-43
29. Pfrommer C, Bastl R, Vieths S, et al. Characterization of naturally occurring pseudoallergens causing chronic urticaria [abstract]. J Allergy Clin Immunol 1996; 97: 367
30. Pigatto PD, Valsecchi RH. Chronic urticaria: a mystery. Allergy 2000; 55 (3): 306-8
31. Giehtbrock K, Flynn S, Andrist D, et al. Oral provocation testing with common dyes and preservatives used by the food industry: our experience over the last five years [abstract]. J Allergy Clin Immunol 1999; 103 (1 Pt 2): S6
32. Kozel MM, Mekkes JR, Bossuyt PM, et al. The effectiveness of a history-based diagnostic approach in chronic urticaria and angioedema. Arch Dermatol 1998; 134 (12): 1575-80
33. Henderson Jr RL, Fleischer Jr AB, Feldman SR. Allergists and dermatologists have far more expertise in caring for patients with urticaria than other specialists. J Am Acad Dermatol 2000; 43 (6): 1084-91
34. Joint Task Force on Practice Parameters. The diagnosis and management of urticaria: a practice parameter. Part I: acute urticaria/angioedema. Part II: chronic urticaria/angioedema. Ann Allergy Asthma Immunol 2000; 85 (6 Pt 2): 521-44
35. Kauppinen K, Juntunen K, Lanki H. Urticaria in children: retrospective evaluation and follow-up. Allergy 1984; 39 (6): 469-72
36. Grunewald SM, Hahn C, Wohlleben G, et al. Infection with influenza A virus leads to flu antigen-induced cutaneous anaphylaxis in mice. J Investig Dermatol 2002; 118 (4): 645-51
37. Asero R. Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria. J Allergy Clin Immunol 2003; 111 (5): 1095-8
38. Molinaro G, Cugno M, Perez M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine (9)-bradykinin. J Pharmacol Exp Ther 2002; 303 (1): 232-7
39. Irons BK, Kumar A. Valsartan-induced angioedema. Ann Pharmacother 2003; 37 (7-8): 1024-7
40. Cicardi M, Zingale LC, Bergamaschini L, et al. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004; 164 (8): 910-3
41. Borazan A, Ustun H, Yilmaz A. Angioedema induced by angiotensin II blocker telmisartan [letter]. Allergy 2003; 58 (5): 454
42. Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 2008; 9 (2): 71-9
43. Preston SL, Briceland LL, Lesar TS. Accuracy of penicillin allergy reporting. Am J Hosp Pharm 1994; 51 (1): 79-84
44. Puchner Jr TC, Zacharisen MC. A survey of antibiotic prescribing and knowledge of penicillin allergy. Ann Allergy Asthma Immunol 2002; 88 (1): 24-9
45. Gadde J, Spence M, Wheeler B, et al. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA 1993; 270 (20): 2456-63
46. Simons F. Urticaria: principles of antihistamine treatment. New York: Marcel Dekker Inc., 2004
47. Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998; 138 (4): 635-8
48. Lippert U, Kruger-Krasagakes S, Moller A, et al. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy- loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995; 4 (4 Pt 2): 272-6
49. Lippert U, Moller A, Welker P, et al. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists [published erratum appears in Exp Dermatol 2002 Aug; 11 (4): 386]. Exp Dermatol 2000; 9 (2): 118-24
50. Kozel MM, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004; 64 (22): 2515-36
51. Zuberbier T, Ifflander J, Semmler C,et al. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Dermato-Venereologica 1996; 76 (4): 295-7
52. Berkun Y, Shalit M. Successful treatment of delayed pressure urticaria with montelukast. Allergy 2000; 55 (2): 203-4
53. Ellis MH. Successful treatment of chronic urticaria with leukotriene antagonists. J Allergy Clin Immunol 1998; 102 (5): 876-7
54. Greaves M, Lawlor F. Angioedema: manifestations and management. J Am Acad Dermatol 1991; 25 (1 Pt 2): 155-61; discussion 61-5
55. Cugno M, Nussberger J, Cicardi M, et al. Bradykinin and the pathophy-| siology of angioedema. Int Immunopharmacol 2003; 3 (3): 311-7
56. Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol 2005; 53 (3): 373-88; quiz 89-92
57. Frigas E, Nzeako UC. Angioedema: pathogenesis differential diagnosis, and treatment. Clin Rev Allergy Immunol 2002; 23 (2): 217-31
58. Lin RY, Cannon AG, Teitel AD. Pattern of hospitalizations for angioedema in New York between 1990 and 2003. Ann Allergy Asthma Immunol 2005; 95 (2): 159-66
59. Lin RY, Shah SN. Increasing hospitalizations due to angioedema in the United States. Ann Allergy Asthma Immunol 2008; 101 (2): 185-92
60. Zingale LC, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. CMAJ 2006; 9 (175): 1065-70
61. Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf 2001; 24 (8): 599-606
62. Ducroix JP, Outurquin S, Benabes-Jezraoui B, et al. Angio-oedemes et in-hibiteurs de l'enzyme de conversion de l'angiotensine: a propos de 19 cas. Revue de Medecine Interne 2004; 25 (7): 501-6
63. Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA 1997; 278 (3): 232-3
64. Agah R, Bandi V, Guntupalli KK. Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome. Intensive Care Med 1997; 23 (7): 793-6
65. Pigman EC, Scott JL. Angioedema in the emergency department: the impact of angiotensin-converting enzyme inhibitors. Am J Emerg Med 1993; 11 (4): 350-4
66. Ohnishi-Inoue Y, Mitsuya K, Horio T. Aspirin-sensitive urticaria: provocation with a leukotriene receptor antagonist. Br J Dermatol 1998; 138 (3): 483-5
67. Sabroe RA, Black AK. Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 1997; 136 (2): 153-8
68. Boxer M. Accupril- and cozaar-induced angioedema in the same patient [letter]. J Allergy Clin Immunol 1996; 98 (2): 471
69. Cha YJ, Pearson VE. Angioedema due to losartan. Ann Pharmacother 1999; 33 (9): 936-8
70. Frye CB, Pettigrew TJ. Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy 1998; 18 (4): 866-8
71. Rivera JO.Losartan-induced angioedema. Ann Pharmacother1999;33(9):933-5
72. Rupprecht R, Vente C, Grafe A, et al. Angioedema due to losartan. Allergy 1999; 54 (1): 81-2
73. Sharma PK, Yium JJ. Angioedema associated with angiotensin II receptor antagonist losartan. South Med J 1997; 90 (5): 552-3
74. van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998; 158 (18): 2063-5
75. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine 1992; 71 (4): 206-15
76. Cooney C, Nagy A. Angio-oedema associated with risperidone [letter]. BMJ 1995; 311 (7014): 1204
77. Kimyai-Asadi A, Harris JC, Nousari HC. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999; 60 (10): 714-25; quiz 26
78. Mithani H, Hurwitz TA. Paroxetine-induced angioedema and tongue swelling [letter]. J Clin Psychiatry 1996; 57 (10): 486
79. Cooper JP, Quarry DP, Beale DJ, et al. Life-threatening, localized angio-oedema associated with streptokinase. Postgrad Med J 1994; 70 (826): 592-3
80. Francis CW, Brenner B, Leddy JP, et al. Angioedema during therapy with recombinant tissue plasminogen activator. Br J Haematol 1991; 77 (4): 562-3
81. Hill MD, Barber PA, Takahashi J, et al. Anaphylactoid reactions and an-gioedema during alteplase treatment of acute ischemic stroke. CMAJ 2000; 162 (9): 1281-4
82. Pancioli A, Brott T, Donaldson V, et al. Asymmetric angioneurotic edema associated with thrombolysis for acute stroke. Ann Emerg Med 1997; 30 (2): 227-9
83. Walls RM, Pollack Jr CV. Successful cricothyrotomy after thrombolytic therapy for acute myocardial infarction: a report of two cases. Ann Emerg Med 2000; 35 (2): 188-91
84. Temino VM, Peebles Jr RS. The spectrum and treatment of angioedema. Am J Med 2008; 121 (4): 282-6
85. Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1 INH activity in women. Lancet 2000; 356 (9225): 213-7
86. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001; 161 (5): 714-8
87. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document [published erratum appears in Clin Exp Immunol 2005 Jul; 141 (1): 189-90]. Clin Exp Immunol 2005; 139 (3): 379-94
88. Gompels MM, Lock RJ, Morgan JE, et al. A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. J Clin Pathol 2002; 55 (2): 145-7
89. Caldwell JR, RuddyS,Austen KF. Assay of complement components C1, C4, C2, C3 and C9 in whole rat serum. Int Arch Allergy Appl Immunol 1972; 43 (6): 887-97
90. Cohen SH, Koethe SM, Kozin F, et al. Acquired angioedema associated with rectal carcinoma and its response to danazol therapy: acquired angioedema treated with danazol. J Allergy Clin Immunol 1978; 62 (4): 217-21
91. Donaldson VH, Hess EV, McAdams AJ. Lupus-erythematosus-like disease in three unrelated women with hereditary angioneurotic edema. Ann Intern Med 1977; 86 (3): 312-3
92. Hauptmann G, Lang JM, North ML,et al. Acquired C1-inhibitor deficiencies in lymphoproliferative diseases with serum immunoglobulin abnormalities: a study of three cases. Blut 1976; 32 (3): 195-206
93. Schreiber AD, Zweiman B, Atkins P, et al. Acquired angioedema with lym-phoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. Blood 1976; 48 (4): 567-80
94. Anonymous. The diagnosis and management of anaphylaxis. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology [published erratum appears in J Allergy Clin Immunol 1998 Aug; 102 (2): 264]. J Allergy Clin Immunol 1998; 101 (6 Pt 2): S465-528
95. Lock RJ, Gompels MM. C1-inhibitor deficiencies (hereditary angioedema): where are we with therapies? Curr Allergy Asthma Rep 2007; 7 (4): 264-9
96. Frank MM. Hereditary angioedema: a half century of progress. J Allergy Clin Immunol 2004; 114 (3): 626-8
97. Trachsel D, Hammer J. A vote for inhaled adrenaline in the treatment of severe upper airway obstruction caused by piercing of the tongue in hereditary angioedema. Intensive Care Med 1999; 25 (11): 1335-6
98. Pekdemir M, Ersel M, Aksay E, et al. Effective treatment of hereditary an-gioedema with fresh frozen plasma in an emergency department. J Emerg Med 2007; 33 (2): 137-9
99. Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007; 98 (4): 383-8
100. Longhurst HJ. Emergency treatment of acute attacks in hereditary angio-edema due to C1 inhibitor deficiency: what is the evidence? Int J Clin Pract 2005; 59 (5): 594-9
101. Friedmann PS. Assessment of urticaria and angio-oedema. Clin Exp Allergy 1999; 29 Suppl. 3: 109-12; discussion 13-5
102. Bernstein JA. Hereditary angioedema: a current state-of-the-art review: VIII. Current status of emerging therapies. Ann Allergy Asthma Immunol 2008; 100 (1 Suppl. 2): S41-6
103. Bork K, Hardt J, Schicketanz KH, et al. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 es-terase inhibitor deficiency. Arch Intern Med 2003; 163 (10): 1229-35
104. Bork K, Koch P. Episodes of severe dyspnea caused by snoring-induced re current edema of the soft palate in hereditary angioedema. J Am Acad Dermatol 2001; 45 (6): 968-9
105. Bork K, Meng G, Staubach P, et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005; 45 (11): 1774-84
106. Farkas H, Harmat G, Fust G, et al. Clinical management of hereditary angio-oedema in children. Pediatr Allergy Immunol 2002; 13 (3): 153-61
107. Zuraw BL. Current and future therapy for hereditary angioedema. Clin Immunol 2005; 114 (1): 10-6
108. Choi G,Soeters MR, FarkasH, etal. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007; 47 (6): 1028-32
109. Longhurst H. Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. Curr Opin Investig Drugs 2008; 9 (3): 310-23
110. Levy JH, O'Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Exp Opin Investig Drugs 2006;15 (9): 1077-90
111. Waton J, Boulanger A, Trechot PH,et al. Contact urticaria from Emla cream. Contact Derm 2004; 51 (5-6): 284-7
112. Krautheim AB, Jermann TH, Bircher AJ. Chlorhexidine anaphylaxis: case report and review of the literature. Contact Derm 2004; 50 (3): 113-6
113. Andrews AW, Fornwald JA, Lijinsky W. Nitrosation and mutagenicity of some amine drugs. Toxicol Appl Pharmacol 1980; 52 (2): 237-44